title: An experimental model of encapsulating peritoneal sclerosis.
abstract: In Japan, only about 3% of all patients with end-stage renal disease are maintained by continuous ambulatory peritoneal dialysis (CAPD). Although the reasons for the low proportion of patients receiving CAPD are multifactorial, encapsulating peritoneal sclerosis (EPS), a fatal complication of CAPD, is a major factor. In 1995 we developed a rat model of EPS, and in 2001 also developed an EPS model in mice. These rodent EPS models are reliable, reproducible, and inexpensive and have been used by other investigators. The renin-angiotensin system negatively regulates the transforming growth factor-beta signaling pathway, which plays a major role in tissue fibrosis. To investigate the anti-EPS effect of renin-angiotensin system inhibition, an angiotensin-converting enzyme inhibitor, quinapril, was administered to an EPS model in mice. Quinapril was found to inhibit EPS, both macro- and microscopically, in a dose-dependent manner. We report our experience of developing the experimental in vivo EPS model, and the inhibitory effect of this angiotensin-converting enzyme inhibitor on EPS.
authors.affiliation: Second Department of Surgery, Dokkyo University School of Medicine, Mibu, Tochigi, Japan. tsawada@dokkyomed.ac.jp
authors.forename: Tokihiko
authors.initials: T
authors.lastname: Sawada
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Ishii
authors.forename: Ichiro
authors.initials: I
authors.lastname: Nakajima
authors.forename: Shohei
authors.initials: S
authors.lastname: Fuchinoue
authors.forename: Keiichi
authors.initials: K
authors.lastname: Kubota
authors.forename: Satoshi
authors.initials: S
authors.lastname: Teraoka
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000818:Animals; D004195:Disease Models, Animal; D007676:Kidney Failure, Chronic / Q000473:pathology / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects*; D010532:Peritoneal Diseases / Q000209:etiology / Q000473:pathology* / Q000517:prevention & control; D010537:Peritoneum / Q000473:pathology*; D011379:Prognosis; D000077583:Quinapril; D012598:Sclerosis; D044005:Tetrahydroisoquinolines / Q000627:therapeutic use
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D044005:Tetrahydroisoquinolines; D000077583:Quinapril